OABI
- OmniAb, Inc.
()
Overview
Company Summary
OmniAb, Inc. (OABI) is a biotechnology company specializing in the development and production of advanced antibody therapeutics. The company utilizes its proprietary OmniAb platform, which consists of genetically engineered animal models, to create fully human antibodies for a wide range of therapeutic applications.
OABI's OmniAb platform offers a unique advantage in antibody discovery and development. With the platform's animal models, OABI can create diverse and high-quality antibody libraries that closely resemble human immune systems. This enables the generation of fully human antibodies with high specificity and low immunogenicity, making them effective and safe for therapeutic use.
The company works closely with its partners, including pharmaceutical companies, biotech firms, and academic institutions, to co-develop novel antibody therapeutics. OABI's aim is to leverage its platform to accelerate the drug discovery process, reduce development timelines, and improve the success rate of antibody-based therapies.
In addition to antibody discovery services, OABI also provides support throughout the drug development process, including antibody engineering, optimization, and production. The company's team of skilled researchers and scientists work collaboratively to design and develop customized therapeutic antibodies that address specific disease targets.
Ultimately, OmniAb, Inc. aims to contribute to the advancement of medical research and provide innovative solutions for treating various diseases and disorders through the development of high-quality, fully human antibody therapeutics.